At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
INM InMed Pharmaceuticals Inc
Post-Mkt 10-15 16:53:24 EDT
1.33
+0.02
+1.53%
盘后1.26
-0.07-5.26%
16:21 EDT
High1.34Low1.31Vol17.59K
Open1.31D1 Closing1.31Amplitude2.29%
Mkt Cap7.31MTradable Cap2.86MTotal Shares5.49M
T/O23.41KT/O Rate0.82%Tradable Shares2.15M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

ADAR1 Capital Management Reports Acquisition of $12,718.7996 in InMed Pharmaceuticals Common Shares
Reuters  ·  14 minutes ago
ADAR1 Capital Management Reports Acquisition of $12,718.7996 in InMed Pharmaceuticals Common Shares
ADAR1 Capital Management Reports $14,530 InMed Pharmaceuticals Common Shares Purchase
Reuters  ·  10-09
ADAR1 Capital Management Reports $14,530 InMed Pharmaceuticals Common Shares Purchase
ADAR1 Capital Management Reports $56,041 InMed Pharmaceuticals Common Share Purchase
Reuters  ·  10-06
ADAR1 Capital Management Reports $56,041 InMed Pharmaceuticals Common Share Purchase
InMed receives Nasdaq notification from listing qualifications department
TIPRANKS  ·  09-19
InMed receives Nasdaq notification from listing qualifications department
InMed Gets NASDAQ Notice After Stockholders’ Equity Falls Below $2.5 Million Minimum
Reuters  ·  09-19
InMed Gets NASDAQ Notice After Stockholders’ Equity Falls Below $2.5 Million Minimum
InMed Says Mentari Merger to Deliver USD 490 Million in Gross Proceeds, Restore NASDAQ Equity Compliance
Reuters  ·  09-19
InMed Says Mentari Merger to Deliver USD 490 Million in Gross Proceeds, Restore NASDAQ Equity Compliance
ADAR1 Capital Management Reports $117,700 InMed Pharma Common Share Purchase
Reuters  ·  09-17
ADAR1 Capital Management Reports $117,700 InMed Pharma Common Share Purchase
InMed FY26 Net Loss Widens to Us$12.9 Million; Discontinued-Ops Sales Drop 36% to Us$3.2 Million
Reuters  ·  09-10
InMed FY26 Net Loss Widens to Us$12.9 Million; Discontinued-Ops Sales Drop 36% to Us$3.2 Million
Mentari Therapeutics Merger with Inmed Set to Close Ahead of USD 200 Million Private Placement
Reuters  ·  07-22
Mentari Therapeutics Merger with Inmed Set to Close Ahead of USD 200 Million Private Placement
Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline
THOMSON REUTERS  ·  07-22
Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline
ADAR1 Capital Acquires 1,000 Inmed Common Shares Worth $1,555
Reuters  ·  07-18
ADAR1 Capital Acquires 1,000 Inmed Common Shares Worth $1,555
Vivo Opportunity Reports USD 32,319 Purchase of Inmed Common Shares
Reuters  ·  07-17
Vivo Opportunity Reports USD 32,319 Purchase of Inmed Common Shares
Inmed Amends Merger Deal with Mentari, Files S-4 Registration Statement
Reuters  ·  07-11
Inmed Amends Merger Deal with Mentari, Files S-4 Registration Statement
InMed Pharmaceuticals amends merger pact with Mentari Therapeutics
TIPRANKS  ·  07-07
InMed Pharmaceuticals amends merger pact with Mentari Therapeutics
Vivo Opportunity Reports $9,963 Purchase of Inmed Pharma Common Shares
Reuters  ·  07-03
Vivo Opportunity Reports $9,963 Purchase of Inmed Pharma Common Shares
Vivo Opportunity reports $371,785 purchase of InMed Pharma common shares
Reuters  ·  06-11
Vivo Opportunity reports $371,785 purchase of InMed Pharma common shares
InMed Pharmaceuticals files Form 3 as Vivo Opportunity discloses beneficial ownership of 541,752 shares
Reuters  ·  06-11
InMed Pharmaceuticals files Form 3 as Vivo Opportunity discloses beneficial ownership of 541,752 shares
InMed Pharmaceuticals regains Nasdaq compliance on $1 minimum bid price rule
Reuters  ·  06-10
InMed Pharmaceuticals regains Nasdaq compliance on $1 minimum bid price rule
InMed regains compliance with Nasdaq continued listing requirements
TIPRANKS  ·  06-05
InMed regains compliance with Nasdaq continued listing requirements
InMed Pharma releases INM-089 age-related macular degeneration presentation
Reuters  ·  06-03
InMed Pharma releases INM-089 age-related macular degeneration presentation

Introduction

Company Name.
InMed Pharmaceuticals Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. The company's prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. Its lead product is INM-755, a cannabinol topical skin cream, which is in Phase 2 clinical trial for the treatment of epidermolysis bullosa. The company is also developing INM-088, which is in preclinical studies for the treatment of glaucoma; INM-405 for the treatment of pain; and cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. In addition, it offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Issue price:
--